Literature DB >> 31366806

Why Did the Patient Not Show Any Neurological Symptoms on the Day of the Higher Serum Concentration of Ceftriaxone?

Takahiko Fukuchi1, Hitoshi Sugawara1.   

Abstract

Entities:  

Keywords:  ceftriaxone; concentration; encephalopathy

Mesh:

Substances:

Year:  2019        PMID: 31366806      PMCID: PMC6949438          DOI: 10.2169/internalmedicine.3293-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
To the Editor We read with interest an article entitled “Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentration in a Hemodialysis Patient” by Suzuki et al. in the Internal Medicine Advanced publication (1). The authors carefully described the clinical course of a patient who suffered from encephalopathy, possibly caused by ceftriaxone. The authors carefully deduced the causes of encephalopathy, most of which were highly inductive. A previous pharmacokinetic study revealed lower serum concentrations of ceftriaxone among hemodialysis patients (2) in comparison to the concentration recorded in this patient (>100 μg/mL) (1). Additionally, the cerebrospinal concentration (10.2 μg/mL) of ceftriaxone in this encephalopathic patient was higher in comparison to meningitis patients (median 3.52 μg/mL), whose blood-brain barrier might be more permeable, allowing medicines to penetrate more easily from blood into the cerebrospinal fluid (3). Thus, high serum and cerebrospinal fluid concentrations might explain ceftriaxone's pathogenicity. However, these facts cannot clarify the definite cause of encephalopathy, because her symptoms and her serum concentration did not show a directly linear relationship (1). That is, she had no consciousness disturbance, despite the high concentration of ceftriaxone on day 9 after administration of this third-generation cephaorosporin. We would like to ask the authors why she did not show any neurological symptoms when the concentration of the drug was higher.

The authors state that they have no Conflict of Interest (COI).
  3 in total

1.  Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations.

Authors:  Sarah Allegra; Chiara Simona Cardellino; Giovanna Fatiguso; Jessica Cusato; Amedeo De Nicolò; Valeria Avataneo; Stefano Bonora; Antonio D'Avolio; Giovanni Di Perri; Andrea Calcagno
Journal:  J Clin Pharmacol       Date:  2018-06-06       Impact factor: 3.126

2.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

3.  Encephalopathy Induced by High Plasma and Cerebrospinal Fluid Ceftriaxone Concentrations in a Hemodialysis Patient.

Authors:  Soichiro Suzuki; Shotaro Naito; Yoshiyuki Numasawa; Mizuho Asada; Norikazu Shoji; Moko Zeniya; Daiei Takahashi; Hidehiko Sato; Soichiro Iimori; Naohiro Nomura; Eisei Sohara; Tomokazu Okado; Yasuyoshi Ishiwata; Masashi Nagata; Tatemitsu Rai; Takanori Yokota; Shinichi Uchida
Journal:  Intern Med       Date:  2019-02-25       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.